Drugs / CRCL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02409524 | Jul 2016 → Jun 2017 | adult hepatocellular carcinoma | Mirror Biologics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRCL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02409524 ↗ |
| Modality | Protein / enzyme biologic | “Autologous tumor-derived chaperone protein mixture” NCT02409524 ↗ |
| Route | Other | “monthly (every 28 days) ID injections of CRCL alone” NCT02409524 ↗ |